155 results
8-K
EX-99.1
ACST
Acasti Pharma Inc.
9 Aug 24
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
8:00am
value of our derivative warrant liabilities, offset in part by a $1.6 million increase in research and development expenses.
Total research … )
Operating expenses
Research and development expenses, net of government assistance
General and administrative expenses
Restructuring cost
Loss from operating
424B3
ACST
Acasti Pharma Inc.
7 Aug 24
Prospectus supplement
4:14pm
team possesses significant experience in drug formulation and drug delivery research and development, clinical and pharmaceutical development … Paid and Net Income (Loss)
Due to the nature of our consolidated financial statements and primary focus on research and development of novel
8-K
EX-99.1
uozggcr4vorl2srbptt4
21 Jun 24
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
8:00am
8-K
EX-99.1
dh163
12 Feb 24
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
8:00am
8-K
EX-99.1
586tz g2m5vwbz
13 Nov 23
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
12:00am
424B3
vbmqd7 b0rffheodenh9
16 Oct 23
Prospectus supplement
4:31pm
8-K
EX-99.1
9nxevb6
11 Aug 23
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
7:31am
8-K
EX-99.1
z5dlth8z2d
23 Jun 23
Acasti Pharma Reports Fiscal Year 2023 Operational Results
7:31am
8-K
EX-99.1
ia496i bm
14 Nov 22
Acasti Pharma Reports Second Quarter 2023 Operational Results
7:15am